Search Results 2891-2900 of 18427 for rheumatoid arthritis

  1. Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study - Mayo Clinic

    (GFR) with a correction factor for African American race creatinine clearance for trial eligibility, where GFR >= 30 mL/min/1.73m^2 will be considered ...

  2. MMRC Horizon One Adaptive Platform Trial Evaluating Therapies In RRMM - Mayo Clinic

    ... factor support is allowed for hematologic parameters as long as the investigator deems the participant otherwise fit for screening) * Adequate hepatic ...

  3. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma - Mayo Clinic

    Patients must not have received lenalidomide previously. Growth factor(s): must not have received within 2 weeks of entry onto this study; Steroids: patients ...

  4. First-in-Human Study of KO-947 in Non-Hematological Malignancies - Mayo Clinic

    Evidence of visible retinal pathology as assessed by ophthalmologic examination that is considered a risk factor for retinal vein thrombosis or neurosensory ...

  5. Joel Streed | Mayo Clinic News Network - Page 25 of 170

    Because[...] By Joel Streed • April 21, 2022. New study finds rheumatology prescribing, spending linked to pharmaceutical payments. On April 1, the review and ...

  6. Medical Research & Education - Mayo Clinic News Network

    Featured News. Mayo Clinic finds surprising results on first-ever test of stem cell therapy to treat arthritis. Kevin Punsky. December 6, 2016. How one minute ...

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Arthritis, Thyroid cancer, Thyroid nodule, Abscess, Liver problems, Hepatocellular carcinoma, Infection, Bone metastasis, Pneumothorax, Pleural effusion ...

  8. News - Integrated Systems Biology and AI — Tailored Pharmacology and Precision Medicine: Hu Li - Mayo Clinic Research

    A key transcription factor unlocks new potential in stem cell-based embryo models (Dec. 4, 2024); Mayo Clinic unveils cutting-edge AI for precision cancer ...

  9. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma - Mayo Clinic

    Hematopoietic growth factor, at least 14 days from last dose; or; Study drug, 30 days or 5 half-lives, whichever is longer, from last dose. Patient ...

  10. Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer - Mayo Clinic

    ... factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z ...